Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Compugen's interest expense for the
three
months ended in Mar. 2026 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Compugen's Operating Income for the
three
months ended in Mar. 2026 was $ -9.02 Mil. Compugen's Interest Expense for the
three
months ended in Mar. 2026 was $ 0.00 Mil.
GuruFocus does not calculate Compugen's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Compugen (NAS:CGEN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Compugen's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
GuruFocus does not calculate Compugen's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Compugen Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Compugen Interest Expense Historical Data
* Premium members only.
The historical data trend for Compugen's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compugen (CGEN) has a Interest Expense of $-0.03 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Compugen and its competitors.
Is Compugen's Interest Expense too high?
Compugen's current Interest Expense is $-0.03 Mil. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's Interest Expense compare to VRTX and REGN?
Compugen's Interest Expense of $-0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Compugen and its competitors. Compugen's current Interest Expense is $-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.31, compared to a current price of $2.16 — trading 59.4% below its estimated fair value. The current Interest Expense is $-0.03 Mil. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Compugen (CGEN), the current Interest Expense is $-0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compugen (CGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Compugen stock appears to be undervalued.
The current stock price of $2.16 is trading 59.4% below its estimated GF Value™ of $5.31.
GuruFocus considers Compugen to be Possible Value Trap.
Key valuation signals for CGEN:
Interest Expense: $-0.03 Mil
GF Value™: $5.31 vs. price of $2.16 (59.4% below fair value)
No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score
Get the complete analysis for CGEN
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGEN has been successfully added to your 
